Clinical trial · Interventional
Ovarian Tissue Cryopreservation and Subsequent Auto-Transplantation for Female Cancer Patients
NCT05830929CI-TRIAL-00100365recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ovarian Tissue Cryopreservation will be provided to cancer patients to allow them to have their fertility preserved.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ovarian tissue freezing and subsequent auto-transplantation after thawing | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ovarian tissue freezing and subsequent auto-transplantation after thawing
- description
- Ovarian tissue freezing and subsequent auto-transplantation after thawing
- interventionNames
- Procedure: Ovarian tissue freezing and subsequent auto-transplantation after thawing
Primary outcomes (1)
- measure
- Surgical complications
- timeFrame
- 15 years
- description
- Surgical complications after ovarian tissue transplantation
Secondary outcomes (1)
- measure
- Pregnancy rate
- timeFrame
- 15 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 1 Month
- Maximum age
- 35 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged from 0-35 years old and diagnosed with cancer e.g., leukaemia, myeloproliferative or myelodysplastic diseases, lymphoma, bone tumours, neurological neoplasms and sarcoma, Paediatric bone marrow transplant patients * Patients with any illness or who will undergo any type of treatment that may cause irreversible damage to their fertility, such as extensive abdominal surgery, high toxicity medication and treatments; * Patients suffering from hormone-sensitive malignancies who will undergo medical treatment, such as radiotherapy and chemotherapy that is liable to damage their ovaries and deter them from conception in the future. Exclusion Criteria: * Patients with no anticipated oncologic therapies * Patients who are pregnant * Children with one ovary * Children deemed high risk for perioperative complications * Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
References
Publications (0)
Data not yet available
No reference posted for this study.